IASLC World Conference on Lung Cancer

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference on Lung Cancer.

The bispecific T-cell engager tarlatamab showed continued efficacy and tolerable safety, according to follow-up from the phase 2 DeLLphi-301 study.

Firmonertinib showed efficacy and safety in patients with EGFR PACC-mutated non–small cell lung cancer.

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among patients with small cell lung cancer.

Datopotamab deruxtecan for the treatment of advanced non–small cell lung cancer is ongoing investigation in multiple clinical trials.

In patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.

Investigators reported the best objective response, progression-free survival, overall survival, and safety of a B7-H3–directed antibody-drug conjugate at the 2023 World Conference on Lung Cancer.

According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non–small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial.

Patritumab deruxtecan showed clinically meaningful and durable efficacy in the phase 2 HERTHENA-Lung01 trial of patients with advanced EGFR-mutated non–small cell lung cancer.

According to Shirish M. Gadgeel, MD, adagrasib demonstrated durable clinical benefit [and] there were no new safety signals.

Sitravatinib plus tislelizumab showed a confirmed investigator-assessed overall response rate of 30.4% in PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.

Luciano Mutti, PhD, professor in cancer research, University of Salford, Manchester, discusses the current and future role of immunotherapy in mesothelioma. 

Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.

Durvalumab treatment in the second-line setting or beyond demonstrated clinical benefit and led to durable responses in heavily pretreated patients with locally advanced or metastatic non-small cell lung cancer.

Determining the PD-L1 status of a patient’s tumor has become increasingly important for informing the clinical decision whether to offer certain immunotherapeutic agents, making standardization of the tests and antibodies used to determine the PD-L1 status necessary to provide accurate and consistent results.

Treatment with icotinib more than doubled intracranial progression-free survival (iPFS) compared with whole brain irradiation (WBI) combined with standard chemotherapy.

Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy, according to phase III clinical trial results.

Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer. He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.